NEJM January 2026 Fremanezumab in Children and Adolescents with Episodic Migraine

This study investigated whether fremanezumab, a treatment already used by adults, could effectively reduce the frequency of episodic migraines in children and adolescents. By comparing monthly injections of the drug against a placebo, researchers found that young patients experienced a significant decrease in monthly migraine days and a reduction in the severity of their headaches. Notably, nearly half of the participants receiving the medication saw their migraine frequency cut by at least 50%, suggesting a strong therapeutic benefit. While the drug was generally well-tolerated, with only minor skin redness at the injection site, the authors conclude that continued observation is necessary to confirm the long-term safety and success of this treatment for younger populations.